Transdermal buprenorphine in patients with cancer-related pain in oncological practice

Journal of Applied Therapeutic Research

Volumn 6, Issue 4, 2008, Pages 20-31

  Schmitz, Stephan ^a   Bruch, Harald Robert ^b   Hagen Aukamp, Christa ^c  

^a Practice of Hematology/Oncology   (Germany)

^b Oncological Practice Bonn   (Germany)

^c Oncological Department   (Germany)

Author keywords

Cancer pain; Oncology; Pain; Transdermal buprenorphine

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; BUPRENORPHINE; CORTICOSTEROID; DICLOFENAC; DIPYRONE; FENTANYL; HYDROMORPHONE; IBUPROFEN; MORPHINE; NALOXONE; NAPROXEN; NEUROLEPTIC AGENT; OXYCODONE; PARACETAMOL; ROFECOXIB; SPASMOLYTIC AGENT; TILIDINE; TRAMADOL;

ADULT; ADVANCED CANCER; AGED; ANALGESIA; APPLICATION SITE ERYTHEMA; APPLICATION SITE SWELLING; ARTICLE; CANCER CENTER; CANCER PAIN; CHRONIC PAIN; CLINICAL PRACTICE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBSERVATIONAL STUDY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SKIN ALLERGY; SOMNOLENCE; TREATMENT WITHDRAWAL; VOMITING;

EID: 67649428639     PISSN: 10292659     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Böger RH. (2006). Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliative Medicine, 20:17-23.
2. Böhme K, Likar R. (2003). Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS) in the treatment of patients with chronic pain. A randomized, double-blind, placebo-controlled study. Pain Clinic, 15:193-202.
3. Caplan RA, Southam M. (1990). Transdermal drug delivery and its application to pain. Adv Pain Res Ther, 14:233-240.
4. Clark A et al. (2004). Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Cur Med Res Opin, 20(9):1419-1428.
5. Cleeland CS. (1998). Under-treatment of cancer pain in elderly patients. JAMA, 279(23):1914-1915.
6. Christoph T, Kögel B, Schiene K et al. (2005). Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol, 507; 87-98.
7. Crook J, Rideout E, Brown G. (1984). The prevalence of pain complaints in a general population. Pain, 18:299-314.
8. Dahan A, Yassen A, Bijl H et al. (2005). Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth, 94:825-834.
9. Dertwinkel R, Donner D, Zenz M et al. (1998). Opioids in chronic pain. Baillière Clin Anaesth, 12:39-52.
10. Filitz J, Griessinger N, Sittl R et al. (2006). Effects of intermittent haemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain, 10(8):743-748.
11. Fine PG, Miaskowski C, Paice JA. (2004). Meeting the challenges in cancer pain management. J Support Oncol, 2 (Suppl 4):5-22.
12. Foley KM. (2000). Controlling cancer pain. Hosp Pract (Minneap), 35(4):101-108.
13. Griessinger N, Sittl R, Likar R. (2005). Transdermal buprenorphine in clinical practice - a post-marketing surveillance study of 13, 179 patients. Curr Med Res Opin, 21:1147-1156.
14. Gough S. (2005). Postmarketing surveillance: a UK/European perspective (2005) Curr Med Res Opin, 21(4):565-570.
15. Grond S, Radbruch L, Lehmann KA. (2000). Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinetics, 38:59-89.
16. Grossman SA, Sheidler VA. (2000). Cancer pain. In: Abeloff MD, Armitage JO, Niederhuber MD, et al, Eds. Clinical Oncology. 2nd Ed. New York, NY. Churchill Livingstone, pp. 529-553.
17. Hand CW, Sear JW, Uppington J, Ball MJ. (1990). Buprenorphine deposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth, 64:276-282.
18. Heel RC, Brogden RN, Speight TM, Avery GS. (1979). Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs, 17(2):81-110.
19. Higginson I. (1997). Epidemiologically based needs assessment for palliative and terminal care. Oxford, UK. Radcliffe Medical Press.
20. Kaiko RF, Wallenstein SL, Roger AG et al. (1982). Narcotics in the elderly. Medicine Clinics of North America, 66(5):1079-1089.
21. Koppert W, Ihmsen H, Köber N et al. (2005). Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain, 118:15-22.
22. Likar R, Korak-Leiter M, Lanner G et al. (2005). Efficacy and safety of transdermal buprenorphine in patients over and under 65 years of age. 11th World Congress of Pain, Sydney, August 21-26, 2005. Abstract No. 1793, P296.
23. Martin K, Bégaud B, Latry P et al. (2003). Differences between clinical and postmarketing use. Br J Clin. Pharmacol, 57(1):86-92.
24. McQuay HJ, Moore RA, Bullingham R E S. (1986). Buprenorphine pharmacokinetics. Adv Pain Res Ther, 8:271-278.
25. Mercadante S, Arcuri E. (2004). Opioids and renal function. J Pain, 5:2-19.
26. Muriel C, Failde I, Micó JA et al. (2005). Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicentre, open-label, uncontrolled, prospective, observational clinical study. Clin Ther; 27:451-462.
27. Radbruch L, Sabatowski R, Petzke F et al. (2001). Transdermal fentanyl for the management of cancer pain: a survey of 1, 005 patients. Palliat Med, 15:309-321.
28. Sittl R. (2006). Transdermal buprenorphine in cancer pain and palliative care Palliat Med, 20 Suppl 1 S25-30.
29. Sittl R, Griessinger N, Likar R. (2003). Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicentre, randomized, double-blind, placebo-controlled trial. Clin Ther, 25:150-168.
30. Sittl R, Nuijten M, Poulsen Nautrup B. (2005). Changes in the prescribed daily dosages of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort survey. Clin Ther, 2005;27:1022-1031.
31. Sorge J Sittl R (2004). Transdermal buprenorphine in the treatment of chronic pain: results of a Phase III, multicentre, randomized, double-blind, placebo-controlled study. Clin Ther, 26:1808-1820.
32. ® Summary of Product Characteristics. 2007. Grünenthal GmbH Aachen, Germany.
33. Walsh SL, Preston KL, Stitzer ML et al. (1994). Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther, 55:569-580.
34. World Health Organisation (1996). Cancer pain relief. With a guide to opioid availability. Second edition, Geneva.
35. Zech DF, Grond S, Lynch J et al. (1995). Validation of World Health Organization guidelines for cancer pain relief: A 10-year prospective study. Pain, 63:65-76.